The Effect of Tadalafil 5 mg on Erection and Persistent Storage Lower Urinary Tract Symptoms after Transurethral Resection of Prostate

Diaa-Eldin Taha¹, Ali Ibrahim¹*, Eslam Shokry¹, Khaled Magdy Zeinelabden¹, Salah Elmekawy¹, Ibrahem Ismail Samaha², Tarek Abdelbaky¹ and Hossam Nabeeh¹

¹Department of Urology, Faculty of Medicine, Kafrelsheikh University, Egypt
²Department of Urology, Faculty of Medicine, Zagazig University, Egypt

*Corresponding Author: Ali Ibrahim, Lecturer of Urology, Department of Urology, Faculty of Medicine, Kafrelsheikh University, Egypt.

Received: September 16, 2024; Published: September 23, 2024

Citation: Ali Ibrahim., et al. “The Effect of Tadalafil 5 mg on Erection and Persistent Storage Lower Urinary Tract Symptoms after Transurethral Resection of Prostate”. Acta Scientific Paediatrics 7.10 (2024): 03-09.

Abstract

Objectives: Ato assess the effect of early tadalafil 5 mg once daily on persistent storage lower urinary tract symptoms (LUTS) and erectile function after transurethral resection of the prostate (TURP).

Methods: We conducted double-blind, randomized controlled trial in which all patients underwent TURP. Patients were categorized into group A, who received tadalafil 5 mg once daily after surgery, and group B, who received a placebo. Patients were evaluated using the International Index of Erectile Function (IIEF-5) questionnaire to assess the erectile function, the International Prostate Symptom Score (IPSS).

Results: 195 patients were enrolled. The mean (±SD) IIEF in group A was 11.59 ± 1.9, 19.8 ± 1.12, 20.97 ± 0.72, while in group B, 4.88 ± 0.82, 12.86 ± 1.56, 15.32 ± 1.28 at (1, 3, 6 months) post-TURP, respectively (P < 0.001). The mean (±SD) IPSS in group A was 7.31 ± 1.66, 4.46 ± 0.97, 2.33 ± 0.69, while in group B 9.62 ± 3.34, 5.4 ± 1.98, 2.83 ± 1.27 at (1, 3, 6 months) post-TURP, respectively (P < 0.001). The mean (±SD) pre-operative storage symptom sub-score in group A was 3.05 ± 0.78, 1.63 ± 0.49, 0.92 ± 0.67, while in group B was 3.22 ± 0.72, 2.48 ± 0.5, 1.69 ± 0.47 at (1,3, 6 months) post-TURP, respectively (P < 0.001).

Conclusion: Tadalafil 5 mg daily monotherapy after TURP can early improve erectile function, however; it has a slight improvement on persistent storage LUTS post TURP.

Keywords: Tadalafil 5 mg; Storage LUTS; Erectile Function

Introduction

Men with LUTS due to Benign Prostatic Hyperplasia (BPH) have a higher incidence of ED [1], and LUTS themselves represent an independent risk factor for ED, triggering a significant negative impact on quality of life (QoL). The underlying pathophysiological links between LUTS secondary to BPH and ED are not yet completely understood, even though several determinants are shared by these two clinical entities [2,3].

TURP is considered the gold standard management of BPH despite the new minimally invasive surgical options [4,5]. However, the impact of TURP on sexual function still remains uncertain, Recent studies have shown a negative impact and others have shown improvement in sexual function in patients suffering from ED [6,7].

TURP can cause ED by a variety of mechanisms primarily through a thermal injury that has spread to the cavernous nerves during surgery. Other potential mechanisms include the psychological effect of surgery and the cessation of sexual activity in the postoperative period [8].

Previous studies have reported that some patients had postTURP persistent irritative symptoms and require postoperative medication to treat continuous urinary symptoms. These symptoms are important factors in the patients’ decreased quality of life after surgery. In selecting patients for TURP, predicting the persistence of irritative bladder symptoms is important, but studies investigating the prognostic factors of bladder irritation are uncommon. According to a recent report, postoperative irritative bladder symptoms may remain if there is a severe irritative bladder symptom before the surgery or if there is frequent nocturia [9].

Phosphodiesterase type 5 inhibitors (PDE5-Is) were approved for the treatment of ED, but they have been also demonstrated as highly effective in blunting LUTS in men with or without ED [1013]. Indeed, PDE5-Is act on the relaxation of the bladder neck, and prostate by increasing nitric oxide in smooth muscle, allowing a direct action on micturition phases and not only penile erection [14,15]. Another study demonstrates that once daily 5 mg tadalafil is a potentially effective and safe treatment choice with excellent tolerability for patients with LUTS [16].

Currently, tadalafil 5 mg once daily has been approved for the treatment of LUTS with or without coexisting ED [3]. Another study reported that Tadalafil 5 mg once daily improved LUTS in men without ED by a magnitude similar to that observed in men with ED [17].

The mainstay of medical treatment after radical prostatectomy (RP) to restore spontaneous erectile function remains phosphodiesterase (PDE5) inhibitors, although data from animal studies suggesting that PDE5 inhibitors can prevent smooth muscle apoptosis and fibrosis have not yet been extrapolated to humans because of a lack of standardized protocols. This suggests that a concept of early penile intervention would be promising for those patients who wish to remain sexually active [18].

Tadalafil once daily was most effective on drug-assisted erectile function in men with erectile dysfunction following radical prostatectomy, and tadalafil once daily provided early recovery of erectile function after prostatectomy and possibly protecting from penile structural changes. Unassisted erectile function was not improved after cessation of active therapy for 9 months [19].

To obviate whether it is of value to start tadalafil early after TURP or not? we carried out this study, intending to assess the efficacy of early daily tadalafil 5 mg on persistent storage symptoms and erectile function after TURP.

Materials and Methods

After institutional board review, the study was carried out between May 2021 and October 2022 in a tertiary hospital. The patients were diagnosed with BPH and underwent TURP either Monopolar or Bipolar. Informed consent was obtained from all patients, and the institutional ethics committee approved the study. Patients were randomized into two groups; the first group (A) patients who received tadalafil 5 mg once daily and the second group (B) patients who received a placebo.

All the patients were sexually active before TURP. Sexually inactive patients were excluded from analyses regarding sexual function due to established limitations of the IIEF in quantifying the sexual function of sexually inactive men.

A pertinent medical history was obtained. The patients were evaluated using the International Index of Erectile Function (IIEF-5) questionnaire to assess the erectile function, the International Prostate Symptom Score (IPSS), storage symptoms were assessed by IPSS storage symptom subscore-15, uroflowmetry, pelvi-abdominal ultrasonography with PVR estimation and laboratory investigations (urine analysis, urine culture, kidney function, complete blood count, coagulation profile, and prostate-specific antigen [PSA]). The evaluation time was unified before TURP and one month, 3 months, and 6 months after TURP.

Randomization

Patients were divided into two groups using simple randomization (1:1); group A received early tadalafil 5 mg one week after TURP, while the other group (group B) placebo medication (Control group). The randomization was double-blinded (blinded to the patient and surgeon as well). Study completion and reporting will be carried out following the Consolidated Standards of Reporting Trials (CONSORT) (Figure 1).

Sample size

The sample size was determined a priori using power analysis (G*Power, version 3.1.9.2). Power analysis was conservatively based on three elements: the storage symptoms resolved after TURP, erectile function post-TURP, and LUTs alleviation post-TURP. Type I statistical error of &lt; 5%; and type II statistical error of &lt; 20%. Given the preceding considerations, a sample size of 105 patients in each group was estimated. This sample size provided 80% statistical power and accounted for a 20% dropout rate.

Assessment

Primary outcome: to assess the effect of early tadalafil 5 mg once daily on persistent storage lower urinary tract symptoms (LUTS) and erectile function after transurethral resection of the prostate (TURP). The secondary outcome is to assess the compliance and adverse effects related to the use of tadalafil.

Statistical analysis

Data analysis was performed using the software SPSS (Statistical Package for the Social Sciences) version 26. Categorical variables were described using their absolute frequencies and were compared using the chi-square test and Fisher exact when appropriate. Quantitative variables were described using their means and standard deviations or median and interquartile range according to the type of data. To compare quantitative data between two groups, the independent sample t-test (for normally distributed data) and Mann-Whitney test (for not normally distributed data) were used. To compare one variable over two points of time within one group (paired sample t-test for normally distributed data) and (Wilcoxon signed rank test for not normally distributed data) were used. The level of statistical significance was set at P < 0.05. A highly significant difference was present if p ≤ 0.001.

Results

Around 195 patients were enrolled. Patients were categorized into group A (103), who received tadalafil 5 mg once daily, and group B (92), who received a placebo. There is a statistically nonsignificant difference between the studied groups regarding age, BMI, and medical comorbidities (Table 1).

Regarding the erectile function, in group A, there is a significant improvement in IIEF. The mean (±SD) IIEF in group A before TURP was 9.84 ± 2.6 while post-TURP was 11.59 ± 1.9, 19.8 ± 1.12, 20.97 ± 0.72 at (1, 3, 6 months), respectively (P < .001), while in group B, in comparison with IIEF before TURP 10.43 ± 2.81 there is a significant decrease in IIEF at one month after TURP 4.88 ± 0.82, however, a slight improvement in IIEF at (3, 6 months) post-TURP 12.86 ± 1.56, 15.32 ± 1.28, respectively (P < 0.001) (Table 2).

Concerning the overall LUTS, there is a comparable improvement in IPSS, Qmax, and PVR in both groups. The mean (±SD) IPSS in group A before TURP was 24.18 ± 2.41 while post-TURP was 7.31 ± 1.66, 4.46 ± 0.97, 2.33 ± 0.69 at (1, 3, 6 months), respectively (P < .001), while in group B, the mean (±SD) IPSS before TURP was 24.08 ± 2.63 and 9.62 ± 3.34, 5.4 ± 1.98, 2.83 ± 1.27 at (1,3, 6 months) post-TURP, respectively (P < 0.001).

The mean (±SD) Qmax in group A preoperative was 7.54 ± 2.45 while postoperative was 16.05 ± 2.05, 20.32 ± 3.15, 23.41 ± 3.38 at (1, 3, 6 months), respectively (P < .001), while in group B, the mean (±SD) Qmax preoperative was 8.27 ± 2.28 and 15.22 ± 2.0, 19.00 ± 2.1, 21.56 ± 3.59 at (1,3, 6 months) postoperative, respectively (P 06 < 0.001). The (median) PVR in group A preoperative was 100 while postoperative was 40, 20, and 10 at (1, 3, and 6 months), respectively (P 0.2 ), while in group B, the (median) PVR preoperative was 110 and 40, 20, 10 at (1,3, 6 months) postoperative, respectively (P = 0.2).

However, we found in group A that there is a slight improvement in persistent storage symptoms than in group B, The mean (±SD) pre-operative storage symptom sub-score in group A was 8.63 ± 1.82 while post-TURP was 3.05 ± 0.78, 1.63 ± 0.49, 0.92 ± 0.67 at (1, 3, 6 months), respectively (P < .001), while in group B, the mean (±SD) pre-operative storage symptom sub-score was 8.03 ± 0.22 and 3.22 ± 0.72, 2.48 ± 0.5, 1.69 ± 0.47 at (1, 3, 6 months) postTURP, respectively (P < 0.001) (Table 3).

Almost all patients were compliant with daily tadalafil. As regard the adverse effect, only 13 patients experienced slight headache and runny nose for a shorter time, Moreover, they didn’t discontinue the tadalafil daily use.

Discussion

PDE5-I treatment was more effective than placebo treatment in patients with ED after nerve-sparing radical prostatectomy contributing to the recovery of EF after prostatectomy and possibly protecting from penile structural changes [20].

The same in our study and to the best of our knowledge, this is the first trial comparing the effect of post-TURP early tadalafil-5 mg administration on the persistent storage symptoms and erectile function.

In elderly men, ED and LUTS related to benign prostatic enlargement (BPE) represent a high prevalence comorbid condition with a negative impact on the patient’s QoL and a significant economic burden. It has been established in preclinical and clinical trials that besides aging, several metabolic factors affect the onset and worsening of both ED and LUTS, concurring to penile and nerve alterations and also prostate enlargement and inflammation [21].

TURP is known to be the most effective of all the traditional surgical methods. Once the bladder is free from the obstruction, the thickened bladder wall undergoes atrophy, and its elasticity is restored, thus improving the irritative symptoms. The degree of improvement is reported to be especially high in patients with severe preoperative irritative symptoms [22].

However, a recent study suggested that TURP does not improve irritation symptoms in every patient, and 20% to 30% of patients require medication postoperatively due to persistent irritative symptoms, thus leading to a decrease in quality of life. Significant improvements in LUTS have been yielded by several clinical studies on PDE5-Is. Although the precise mechanism for ameliorating LUTS with PDE5-Is remains unclear, the proposed contributors include relaxing smooth muscle cells in the urogenital tract via the NO/cGMP/PDE5 pathway [23].

In our study, we found that in group A, there is a significant improvement in erectile function, the mean (±SD) IIEF in group A before TURP was 9.84 ± 2.6 while post-TURP was 11.59 ± 1.9, 19.8 ± 1.12, 20.97 ± 0.72 at (1, 3, 6 months), respectively (P < .001), but Regarding overall LUTS, there is a comparable improvement in IPSS, Qmax and PVR in both groups. However, we found in group A that there is a slight improvement in persistent irritative symptoms. The mean (±SD) pre-operative storage symptom sub-score was 8.63 ± 1.82 while post-TURP was 3.05 ± 0.78, 1.63 ± 0.49, 0.92 ± 0.67 at (1, 3, 6 months), respectively (P < .001), as in the first systematic review about the use of PDE5-Is for LUTS, Laydner., et al. reported that PDE5-Is improve IPSS score and IIEF-5 but not Qmax [24].

In agreement with our study, Several RCTs demonstrated that PDE5-Is can significantly decrease IPSS score, ameliorating both storage and voiding LUTS, and improve patients’ QoL [25]. Likewise, in a meta-analysis, IPSS and IIEF scores, but not Qmax, were significantly improved by PDE5-Is [26]. Another study revealed that tadalafil was efficacious and well tolerated in treating ED and LUTS in sexually active men with both conditions. Improvements in both conditions were significant regardless of baseline severity [27].

This study is the first prospective trial of penile rehabilitation with tadalafil 5 mg once a day post-TURP. Our study limitations were the small sample size, so the study should be refashioned in a larger scale of population. Moreover, the study didn’t compare the patients who received tadalafil on demand with the patients who received tadalafil early.

Conclusion

In comparison to placebo, early Tadalafil 5 mg daily monotherapy after TURP can improve erectile dysfunction. We found that tadalafil 5 mg has a slight improvement in persistent storage symptoms post-TURP.

Disclosure

There is no conflict of interest.

Author Contributions

Ali Ibrahim: methodology, idea formulation, and reference collection. Diaa-Eldin Taha: review writing and revision, editing the final draft. Eslam shokry: formal analysis and data collection. Ibrahem Ismail Samaha: formulation of hypothesis, Manuscript revision. Salah Elmekawy: processed the translation revision. Hossam Nabeeh: data collection and final revision. Tarek Abdelbaky: supervision.

Funding

None.

Ethical Approval

All procedures performed in this study were in accordance with the ethical standards of the institutional research committee and with the 1964 Helsinki Declaration and its later amendments.

Consent

Formal consent was signed by the participants for taking part in this research.

Data Availability Statement

The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.

Bibliography

1. Barbosa JA., et al. “Interactions between lower urinary tract symptoms and cardiovascular risk factors determine distinct patterns of erectile dysfunction: a latent class analysis”. The Journal of Urology 190 (2013): 2177.
2. Gacci M., et al. “Critical analysis of the relationship between sexual dysfunctions and lower urinary tract symptoms due to benign prostatic hyperplasia”. European Urology 60 (2011):809.
3. McVary KT. “Erectile dysfunction and lower urinary tract symptoms secondary to BPH”. European Urology 47 (2005):838.
4. Donovan JL., et al. “A randomized trial comparing transurethral resection of the prostate, laser therapy and conservative treatment of men with symptoms associated with benign prostatic enlargement: the CLasP study”. The Journal of Urology 164 (2000): 65.
5. Reich O., et al. “Techniques and long-term results of surgical procedures for BPH”. European Urology 49 (2006): 970.
6. Pavone C., et al. “Sexual dysfunctions after transurethral resection of the prostate (TURP): evidence from a retrospective study on 264 patients”. Archivio Italiano di Urologia e Andrologia 87 (2015): 8.
7. Zong H T., et al. “The impact of transurethral procedures for benign prostate hyperplasia on male sexual function: a metaanalysis”. Journal of Andrology 33 (2012): 427.
8. Welliver C and Essa A. “Sexual side effects of medical and surgical benign prostatic hyperplasia treatments”. Urologic Clinics 43 (2016): 393.
9. Han K S., et al. “Changing trends in the management of benign prostatic hyperplasia during recent 5 years”. Korean Journal of Urology 46 (2005): 458.
10. Broderick GA., et al. “Effects of tadalafil on lower urinary tract symptoms secondary to benign prostatic hyperplasia in men with or without erectile dysfunction”. Urology 75 (2010): 1452.
11. McVary KT., et al. “Tadalafil relieves lower urinary tract symptoms secondary to benign prostatic hyperplasia”. The Journal of Urology 177 (2007): 1401.
12. Porst H., et al. “Efficacy and safety of tadalafil once daily in the treatment of men with lower urinary tract symptoms suggestive of benign prostatic hyperplasia: results of an international randomized, double-blind, placebo-controlled trial”. European Urology 60 (2011): 1105.
13. Roehrborn C G., et al. “Tadalafil administered once daily for lower urinary tract symptoms secondary to benign prostatic hyperplasia: a dose finding study”. The Journal of Urology 180 (2008): 1228.
14. Filippi S., et al. “Characterization and functional role of androgen-dependent PDE5 activity in the bladder”. Endocrinology 148 (2007): 1019.
15. Gacci M., et al. “Latest evidence on the use of phosphodiesterase type 5 inhibitors for the treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia”. European Urology 70 (2016): 124.
16. Cui J., et al. “Efficacy and safety of 12-week monotherapy with once daily 5 mg Tadalafil for lower urinary tract symptoms of benign prostatic hyperplasia: evidence-based analysis”. Frontiers in Medicine 8 (2021): 744012.
17. Brock G., et al. “Tadalafil once daily in the treatment of lower urinary tract symptoms (LUTS) suggestive of benign prostatic hyperplasia (BPH) in men without erectile dysfunction”. BJU International 112 (2013).
18. Megas G., et al. “Comparison of efficacy and satisfaction profile, between penile prosthesis implantation and oral PDE5 inhibitor Tadalafil therapy, in men with nerve-sparing radical prostatectomy erectile dysfunction”. BJU International 112 (2013): E169.
19. Montorsi F., et al. “Effects of tadalafil treatment on erectile function recovery following bilateral nerve-sparing radical prostatectomy: a randomised placebo-controlled study (REACTT)”. European Urology 65 (2015): 587.
20. Goh H J., et al. “Efficacy of phosphodiesterase type 5 inhibitors in patients with erectile dysfunction after nerve-sparing radical prostatectomy: A systematic review and meta-analysis”. Translational Andrology Urology 11 (2022): 124.
21. Gacci M., et al. “Metabolic syndrome and benign prostatic enlargement: a systematic review and meta-analysis”. BJU International 115 (2015): 24.
22. Kojima M., et al. “Reversible change of bladder hypertrophy due to benign prostatic hyperplasia after surgical relief of obstruction”. The Journal of Urology 158 (1997): 89.
23. Kedia GT., et al. “The nitric oxide pathway in the human prostate: clinical implications in men with lower urinary tract symptoms”. World Journal of Urology 26 (2008): 603.
24. Laydner H K., et al. “Phosphodiesterase 5 inhibitors for lower urinary tract symptoms secondary to benign prostatic hyperplasia: a systematic review”. BJU International 107 (2011):1104.
25. Egerdie R B., et al. “Tadalafil 2.5 or 5 mg administered once daily for 12 weeks in men with both erectile dysfunction and signs and symptoms of benign prostatic hyperplasia: results of a randomized, placebo-controlled, double-blind study”. The Journal of Sexual Medicine 9 (2012): 271.
26. Shindel AW. “2009 update on phosphodiesterase type 5 inhibitor therapy part 1: Recent studies on routine dosing for penile rehabilitation, lower urinary tract symptoms, and other indications (CME)”. The Journal of Sexual Medicine 6 (2009): 1794.
27. Porst H., et al. “Effects of tadalafil on lower urinary tract symptoms secondary to benign prostatic hyperplasia and on erectile dysfunction in sexually active men with both conditions: Analyses of pooled data from four randomized, placebo-controlled tadalafil clinical studies”. The Journal of Sexual Medicine 10 (2013): 2044.

---

Copyright: © 2024 Ali Ibrahim., et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.